This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
...
...
Biology Products:... - In the first experiment involving a natural ... richer plant diversity significantly enhances an ecosystem,s productivity. ... as capturing carbon dioxide, a main contributor to ... Environmental Change Initiative and the Sloan Lindeman Professor ...
... Mental Health (CAMH) has discovered a new form ... with the eye defect retinitis pigmentosa (RP). CAMH ... this disorder, CC2D2A. This scientific advance will ... in brain development, and may help identify ways ...
... Mass., April 23 Aware, Inc. (Nasdaq:,AWRE), a leading ... conference call to discuss the company,s operating results,for the ... at 5:00 p.m.,Eastern Time. CEO Michael Tzannes and CFO ... call is being webcast by Thomson and can be ...
Other Biology News:Brown scientists say biodiversity is crucial to ecosystem productivity 2New gene discovered for new form of intellectual disability 2Aware Announces Q1 2008 Earnings Conference Call 2(Date:12/14/2009)... SAN CARLOS, Calif., Dec. 14 Nektar ... Dennis Winger has been appointed to serve on ... highly-respected biopharmaceutical industry leader with over 35 years ... strategy. ,, "Dennis brings to Nektar extensive industry ... evolution," said Howard W. Robin, President and CEO ...
(Date:12/14/2009)... - Results From a Survey Conducted by UCB ... Industrialized Countries , , - A third ... impacts their enjoyment of the festive ... find shopping for gifts, preparing ... difficult to do, - ...
(Date:12/11/2009)... December 10, 2009 miRagen Therapeutics, Inc., a ... developing innovative microRNA-based therapeutics for cardiovascular and muscle ... that microRNA-206 (miR-206) plays a crucial role in ... Lou Gehrig,s disease) and in neuromuscular synaptic regeneration ... December 11 issue of the journal Science ...
(Date:12/11/2009)... SAN DIEGO, Dec. 11 Ambit Biosciences Corporation ... of Texas M. D. Anderson Cancer Center of the ... 220 Monotherapy E fficacy) Phase 2 ... myeloid leukemia (AML). AC220 is a novel, orally ... specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
Breaking Biology Technology:Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Biology NavigationMedical Navigation